$CRVS News

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call - Slideshow

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Reports Q1 2026 Results; Atopic Dermatitis Program Takes Center Stage (NASDAQ:CRVS)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success

Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains

Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Corvus Pharmaceuticals Filed For Mixed Shelf Registration; Size Not Disclosed

Corvus Pharmaceuticals Filed For Mixed Shelf Registration; Size Not Disclosed

Corvus (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...

Corvus Pharmaceuticals Q4 Earnings Call Highlights

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals (NASDAQ:CRVS) Reports Q4 Earnings Miss Amid Positive Pipeline Data